Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 at Royal Bank of Canada
Repligen (NASDAQ:RGEN – Get Free Report) had its price target hoisted by Royal Bank of Canada from $203.00 to $205.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 28.94% from the stock’s current […]
Repligen (NASDAQ:RGEN – Get Free Report) had its price target hoisted by Royal Bank of Canada from $203.00 to $205.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 28.94% from the stock’s current […]
